[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-pressure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-pressure":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,111,0,25,[9,42,66,79,116,146,183,211,239,266,291,312,344,373,398,416,449,470,492,516,535,582,615,645,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053942","nibp-accuracy-study-for-adult-subject-populations-100053942",false,"NCT07697950","NIBP Accuracy Study for Adult Subject Populations","Non-Invasive Blood Pressure Accuracy Study for Adult Subject Populations","Inclusion Criteria:\n\n1. Age requirement: 18 and over.\n2. Have an upper limb (right OR left side) that fits the cuff size of the device (circumference ranging 17 cm to 40 cm) OR have a thigh (right OR left side) that fits a cuff size of the device (circumference ranging 38 to 50 cm).\n3. Have an arterial line as a standard of care, which measures blood pressure at the aortic root.\n4. Able to provide written informed consent.\n5. Expected to remain in the unit for the duration of the study procedure.\n\nExclusion Criteria:\n\n1. Have previously participated in this study (no subject may participate more than once).\n2. Pregnant and lactating women per site standard of care.\n3. Subjects with peripheral arterial diseases (causing left\u002Fright arm difference)\n4. Hemodynamically unstable subjects at the discretion of the investigator.\n5. Exhibited injuries, deformities, intravenous lines, or other abnormalities that, in the opinion of the Investigator, may prevent proper cuff application or functioning.\n6. Are suffering from infection(s) or immunocompromised patients that require isolation.\n7. PI or designee decision due to subject health conditions","ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to collect NIBP and invasive aortic pressure data from the clinical setting.",[27,28],"Blood Pressure Measurement","Blood Pressure","RECRUITING","2026-07-07",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2025-01-13",{"date":37,"type":21},"2027-12-31",{"name":39,"class":40},"GE Healthcare","INDUSTRY",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100054261","ai-guided-predictions-of-blood-pressure-dysregulation-using-perfusion-index-as-a-novel-biomarker-in-persons-with-spinal-cord-injury-100054261","NCT07699094","AI-Guided Predictions of Blood Pressure Dysregulation Using Perfusion Index as a Novel Biomarker in Persons With Spinal Cord Injury","Inclusion Criteria:\n\n* You have had a spinal cord injury (SCI: C4-T12) for more than one year and the SCI was graded as ASIA Impairment Scale (AIS) A or B (unable to voluntarily move your legs)\n* You can also be a gender and age-matched (±5 years) able-bodied (AB) control subject (similar gender and age to a subject with SCI).\n* Subjects with SCI and AB controls must be between 18 and 75 years of age.\n* If you are going to participate, you must avoid caffeine and alcohol, maintain normal salt and water intake, and avoid strenuous exercise for 24 hours prior to the study visit.\n\nExclusion Criteria:\n\n* You have cardiovascular, kidney, or untreated thyroid disease\n* You have a traumatic brain injury (TBI)\n* You have diabetes mellitus\n* You have an acute illness or infection\n* You are dehydrated\n* You smoke\n* You are pregnant\n* You have broken, inflamed, or otherwise fragile skin\n* Your Body Mass Index (BMI) is more than 30 kg\u002Fm2",true,"75 Years",{"count":51,"type":21},24,[24],"The goal of this clinical trial is to determine if perfusion index (PI) can reliably predict changes in systolic blood pressure (SBP) in persons with spinal cord injury (SCI) during a cool temperature challenge. Participants with SCI can be 18-75 years of age, male or female, neurological level of injury C4-T12, ASIA Impairment Scale (AIS: A or B: motor complete) or gender and healthy age-matched able-bodied (AB) controls.\n\nThe main question this study aims to answer is: can PI reliably predict change in SBP during a cool temperature challenge? We hypothesize that PI can be used as a biomarker of SBP in persons with SCI.\n\nResearchers will compare the relationship of 1) changes in PI and SBP and 2) relationship of changes in other vital signs to SBP, during the cool temperature challenge. The researchers aim to determine if PI can be used as a biomarker of SBP in persons with SCI during a cool temperature challenge (experimental group\u002Farm). Able-bodied controls (control group\u002Farm) will receive the same intervention (cool challenge) as the experimental group.\n\nDuring the study, participants will be asked to wear only shorts and a T-shirt so that their skin can be exposed to the warm and cool temperatures of the 2 rooms.\n\nWe will put put on non-invasive sensors (taped or attached on the surface of your body) to measure PI, BP, and other vital signs. We will record these measurements while you are seated in a wheelchair for 10 minutes in a warm room and up to 90 minutes in a cool room.",[55,28,56,57],"Spinal Cord Injuries (SCI)","Thermoregulation","Perfusion Index",{"date":32,"type":33},{"date":60,"type":21},"2026-07-01",{"date":62,"type":21},"2028-06-30",{"name":64,"class":65},"James J. Peters Veterans Affairs Medical Center","FED",{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":15,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":25,"conditions":72,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":41},"100643127","non-invasive-blood-pressure-accuracy-study-for-adult-subject-populations-100643127","NCT07628296",{"count":20,"type":21},[24],[28,27],"2026-06-29",{"date":60,"type":33},{"date":35,"type":33},{"date":77,"type":21},"2027-06-30",{"name":39,"class":40},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":100,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":41},"100644654","impact-of-transcutaneous-spinal-stimulation-on-blood-pressure-and-orthostasis-in-spinal-cord-injury-100644654","NCT07674511","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury: Short and Long-Term Effects","(SCI)","Inclusion Criteria:\n\n* Individuals with a SCI ≥ 1 year after injury\n* Injury level ≥ T6 (thoracic level)\n* AIS grade A-C\n* Cardiovascular dysfunction characterized by one or more of the following:\n\n  1. Persistent hypotension (SBP \\\u003C 90mmHg)\n  2. Orthostatic hypotension (OH, a drop of 20\u002F10 mmHg in SBP\u002FDBP within 5 minutes of standing\u002Fupright positioning).\n\nAdditionally, experiencing orthostatic symptoms in daily life and\u002For requiring medication to manage OH.\n\nExclusion Criteria:\n\n* Current illness (e.g., infection, a pressure injury that might interfere with the intervention)\n* Ventilator-dependent\n* History of implanted brain\u002Fspine\u002Fnerve stimulators\n* Cardiac pacemaker\u002Fdefibrillator or intra-cardiac lines\n* Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction\n* History of seizures\n* pregnancy\n* Insufficient mental capacity to understand and independently provide consent\n* Deemed unsuitable by the study physician",{"count":88,"type":21},10,[24],"The purpose of this study is to learn whether stimulation applied to the spinal cord through the skin (called transcutaneous spinal stimulation) can help control blood pressure in people with a spinal cord injury.\n\nThe main questions this study attempts to solve:\n\n1. What are the immediate effects of spinal cord transcutaneous stimulation on BP?\n2. Does stimulation produce lasting improvements in BP regulation and subsequently, daily function?",[92,93,94,95,96,97,98,99,28],"Spinal Cord Injuries","Hypotension","Orthostatic Hypotension","Spinal Cord Diseases","Cardiovascular Diseases","Trauma, Nervous System","Central Nervous System Disease","Nervous System Diseases",[101,102,103,104,105],"transcutaneous spinal cord stimulation","spinal stimulations","orthostatic hypotension","blood pressure","neuromodulation","NOT_YET_RECRUITING","2026-06-24",{"date":73,"type":33},{"date":110,"type":21},"2026-09",{"date":112,"type":21},"2028-12",{"name":114,"class":115},"Kessler Foundation","OTHER",{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":48,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":144,"locationsCount":41},"100582854","ketone-ester-and-salt-keas-in-older-adults-100582854","NCT06868719","Ketone Ester And Salt (KEAS) in Older Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Older Adults","KEAS-O","Inclusion Criteria:\n\n* Between the ages of 60-85\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, or cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners)\n\nExclusion Criteria:\n\n* High blood pressure - greater than150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy","50 Years","85 Years",{"count":127,"type":21},35,[24],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.",[131,132,133,134,28],"Salt; Excess","Hypertension","Aging","Inflammation",[28,136,133,134,137],"Salt","Cardiovascular Disease","2026-06-16",{"date":140,"type":33},"2026-06-18",{"date":142,"type":33},"2025-03-06",{"date":37,"type":21},{"name":145,"class":115},"Indiana University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":49,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":168,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100643083","effectiveness-of-neomayor-in-improving-cardiovascular-health-100643083","NCT07633392","Effectiveness of NeoMayor in Improving Cardiovascular Health","Effectiveness of NeoMayor in Improving Cardiovascular Health Status in Chilean Adults","NEOMAYOR","Inclusion criteria\n\n* Age between 55 and 75 years\n* Able to read and understand written instructions\n* Ownership of a smartphone and ability to use it independently\n* Physically inactive, defined as performing less than 30 minutes of daily physical activity or less than 2,5 h a week).\n* Intermediate or high cardiovascular risk, defined as the presence of at least three of the following: Hypertension (history diagnosed by specialist or general practitioner or ≥ 140 mmHg systolic or ≥90 mm Hg diastolic blood pressure at baseline or current antihypertensive treatment);Diabetes Mellitus (history diagnosed by specialist or general practitioner or fasting blood glucose ≥126 mg\u002FdL or current pharmacologic treatment);Obesity (BMI ≥30 kg\u002Fm²); Dyslipidaemia (history diagnosed by specialist or general practitioner or lipid-lowering drugs or baseline total cholesterol ≥ 200 mg\u002FdL or LDL cholesterol ≥100 mg\u002FdL).\n\nExclusion Criteria\n\n* Dementia defined as a score in the Mini-ACE \\\u003C 21\n* Significant limitations for independent mobility, including use of assistive devices, frailty, gait instability, or lower-limb painful conditions limiting physical activity\n* Uncorrected hearing or visual impairment preventing adequate use of a smartphone\n* Chronic neurological, psychiatric, or psychological disorders without regular treatment or follow-up.\n* Present severe alcohol or illicit drug use.\n* Severe or terminal illness.","55 Years",{"count":156,"type":21},240,[24],"This study aims to evaluate the effectiveness of NeoMayor, a mobile health (mHealth) intervention designed to improve cardiovascular health among older adults at elevated cardiovascular risk in Chile. NeoMayor is a smartphone-based application that provides personalized guidance on physical activity, diet, sleep, and mental well-being through a multidomain lifestyle approach.\n\nThis multicenter randomized controlled trial will enroll community-dwelling older adults aged 55 to 75 years recruited from primary healthcare centers in urban and rural settings. Participants will be randomized in a 2:1 ratio to either the NeoMayor intervention or a control group receiving standard health information and usual care. The intervention duration will be four months.\n\nThe primary objective is to determine whether the NeoMayor intervention improves cardiovascular health as measured by the Life's Essential 8 Cardiovascular Health Index. Secondary objectives include evaluating changes in cognitive performance, depressive symptoms, anxiety symptoms, quality of life and physical performance outcomes. The study will also assess feasibility and adherence to digital intervention.",[160,161,162,163,164,165,28,166,167],"Cardiovascular Health Status","Smoking Status","Physical Activity","Diet Quality","Sleep Duration","Body Mass Index","LDL Cholesterol","Fasting Glucose",[169,170,171,172,173],"Cardiovascular Health Index","cardiovascular risk","Life's Essential 8","mhealth","older adults","2026-06-12",{"date":138,"type":33},{"date":177,"type":21},"2026-09-01",{"date":179,"type":21},"2027-05",{"name":181,"class":115},"University of Chile",2,{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":41},"100642680","monitoring-blood-pressure-at-home-and-pharmacy-telehealth-100642680","NCT07623291","Monitoring Blood Pressure at Home and Pharmacy Telehealth","REmote Blood Pressure Monitoring and Pharmacist-Led Telehealth Program in an Emergency Department Transitional Care Clinic","REMAP-BP","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to speak English\n* Seen at UAB's or TGH's Emergency Department-Transitional Care Clinic\n* Blood pressure at Emergency Department-Transitional Care Clinic: Systolic BP ≥ 130 mmHg or Diastolic BP ≥ 80 mmHg\n* Have a cellphone with video capability\n\nExclusion Criteria:\n\n* Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg (i.e. severe range hypertension (HTN) by the 2025 American College of Cardiology\u002FAmerican Heart Association BP guidelines) as they typically are referred to immediate treatment intensification. Since the prevalence of severe HTN is low (i.e.\\\u003C5%) in the US population, exclusion of these individuals will have only a small effect on the study.)\n* Lack of willingness or inability to provide written informed consent\n* Individuals who work overnight or second shift\n* History of known major arrhythmias\n* Currently pregnant or breastfeeding\n* Arm circumference \\>50 cm. \\*The upper limit for the largest BP cuff for oscillometric BP devices is typically 50-52 cm; data from the National Health and Nutrition Examination Survey, 2011-2016 indicated that \\\u003C1% of US adults have an arm circumference \\>50 cm, so this will have minimal effect on our study.",{"count":192,"type":21},420,[24],"The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. The study will enroll 400 participants who are seen at the University of Alabama at Birmingham Emergency Department - Transitional Care Clinic and Tampa General Hospital -Transitional Care Clinic. Half of the participants (200 patients) will be asked to measure blood pressure at home, and half of the participants (200 patients) will continue to receive usual care. Participants who measure blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 6 months.",[132,28],[96,197,198,199,200,201],"Delivery of Health Care","Patient Care Management","Health Services Administration","Telemedicine","Vascular Diseases","2026-06-11",{"date":204,"type":33},"2026-06-15",{"date":206,"type":21},"2027-04-01",{"date":208,"type":21},"2031-01",{"name":210,"class":115},"University of Alabama at Birmingham",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":48,"sex":17,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":41},"100642665","multidimensional-sleep-health-intervention-for-couples-100642665","NCT07603245","Multidimensional Sleep Health Intervention for Couples","DREAM-COUPLES: A Dyadic Multidimensional Sleep Health Intervention","DREAM-COUPLES","Inclusion Criteria:\n\n* Adults aged 30-65 years\n* English-speaking\n* Systolic blood pressure greater than or equal to 120 mmHg (at minimum one individual in dyad)\n* Sub-optimal sleep health (at minimum short\u002Flong sleep duration and\u002For irregular sleep patterns)\n\nExclusion Criteria:\n\n* Optimal sleep health\n* History of cardiovascular disease or cancer\n* Not cognitively able to complete study requirements\n* Known medical conditions that would prevent them from safely participating in the study (severe psychiatric disorders, neurological degenerative disease, substance abuse\u002Fdependence)\n* History of severe depression or high risk of sleep apnea\u002Fuse of a Continuous Positive Airway Pressure (CPAP) device\n* Inability to provide informed consent","30 Years","65 Years",{"count":222,"type":21},50,[24],"The goal of this pilot dyadic study is to adapt a multidimensional sleep health (MDSH) intervention, previously disseminated at the individual level, for relationship partners, determine whether it improves sleep health and aspects of cardiometabolic health, and understand the role of dyadic dynamics in intervention effects.\n\nCan a dyadic MDSH intervention improve sleep health and blood pressure (primary outcomes) in relationship partners?\n\nCan a dyadic MDSH intervention improve anthropometric markers of adiposity, psychosocial indicators, stress, dyadic adjustment and coping, self-rated health (secondary outcomes) in relationship partners?\n\nAs this is a single-arm study, there is no control group. All relationship partners will complete a three-tier screening process, attend two in-person visits to receive intervention materials, have blood pressure measured and sleep data collected using in-office and out-of-office monitors, participate in weekly check-in phone calls with research staff over the 8 weeks to support adherence and complete a voluntary follow-up phone call at 16 weeks to provide additional sleep health information. The multidimensional sleep health promotion intervention is based on evidence-based sleep hygiene education and established behavior change techniques and includes: report-back of sleep health profiles, S.M.A.R.T (specific, measurable, attainable, realistic, and timely) goal-setting and establishing a sleep health plan with a fixed sleep schedule, sleep health coaching and dyadic action planning, self-monitoring, virtual sleep hygiene education, motivational feedback, and addressing light and noise in the sleep environment. Mixed methods will be used to understand implementation metrics, processes, and outcomes to establish the successful completion and future expansion of the intervention within this context.",[28,226,227],"Sleep","Cardiovascular Health",[28,226,227,229,230],"Couples","Dyads","2026-06-10",{"date":174,"type":33},{"date":234,"type":33},"2026-06-08",{"date":236,"type":21},"2027-06",{"name":238,"class":115},"Columbia University",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":264,"locationsCount":41},"100569106","community-based-implementation-of-adapted-stac-100569106","NCT06689930","Community-based Implementation of Adapted STAC","Dissemination and Implementation of a Community-driven Approach to Improve the Health of Women, Infants, and Families: Pre-implementation Phase to Adapt Staying Healthy After Childbirth (STAC)","Inclusion Criteria (Interviews and Focus Groups):\n\n* Belong to the STAC-CAB or Lived Experience Group\n* Aged 18 or older\n\nInclusion Criteria (CBO Staff):\n\n* Staff of CBO participating in PDSA cycle\n* Aged 18 years or older\n\nInclusion Criteria (PDSA-Cycles):\n\n* Pregnant persons greater than or equal to 24 weeks gestation and prior to delivery or postpartum\n* Self-Identify as African American or Black\n* Aged 18 years or older\n* Capable of providing informed consent in English\n* Can follow M•care System use instructions in English\n* Have ownership of a functioning and reliable smartphone to upload and use the M•other App\n* Interested in preventing or managing blood pressure during pregnancy\n\nExclusion Criteria (PDSA-Cycles):\n\n* Persistent second or third trimester bleeding at time of enrollment\n* Premature rupture of membranes in the current pregnancy at time of enrollment\n* Known unrepaired maternal congenital heart disease requiring surgical correction\n* Maternal heart failure\n* Chronic kidney disease specifically requiring dialysis\n* On greater than two antihypertensive medications at time of enrollment",{"count":247,"type":21},46,[24],"This study is being done to adapt the Staying Healthy After Childbirth (STAC) intervention for implementation among Black Women and Birthing Persons (WBP).",[28,132,251,252],"Pregnancy Related","Health Equity",[254,255,256,257,28,258],"Prenatal","Post Partum","Hypertensive Disorders of Pregnancy","Remote Patient Monitoring","Community-Based Participation","2026-06-09",{"date":202,"type":33},{"date":262,"type":33},"2025-05-22",{"date":110,"type":21},{"name":265,"class":115},"University of Wisconsin, Madison",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":289,"locationsCount":182},"100514489","effectiveness-and-adoption-of-the-teltex4bp-intervention-among-adults-with-hypertension-in-nepal-100514489","NCT05979168","Effectiveness and Adoption of the TelTex4BP Intervention Among Adults With Hypertension in Nepal","Effectiveness and Adoption of the Structured mHealth Intervention for Improving Blood Pressure Control (TelTex4BP) Among Adults With Hypertension in Nepal: A Randomized Controlled Trial","TelTex4BP","Inclusion Criteria:\n\n* Clinical diagnosis of hypertension\n* Currently receiving\u002Fprescribed blood pressure-lowering medication for more than three month\n* With uncontrolled blood pressure (\\>140\u002F90mm of Hg)\n* Should have access to a mobile phone\n* Able to read text messages ( by themselves\u002Fwith the help of family)\n\nExclusion Criteria:\n\n* Diagnosed with myocardial infarction, stroke, and kidney failure\n* Severe mental illness, cognitive impairment\n* Pregnant women or in the postpartum period","70 Years",{"count":276,"type":21},500,[24],"Despite evidence of preventing cardiovascular disease (CVD) risk through lifestyle changes, many patients with hypertension (HTN) do not comply with this and suffer from CVD and other complications. A previous study using a structured lifestyle intervention program has reported a 14% decrease in the 10-year risk of developing CVD at one year among hypertensive and diabetes patients. Low and Middle-Income countries (LMICs) struggle with a shortage of health workers to deliver such interventions. In this context, mobile phones can contribute to bridging this gap by incorporating them into the health system for health intervention delivery. There is a need to develop contextual mHealth intervention adapted to local needs and culture and test its effectiveness in LMIC settings like Nepal. Our previous small-scale pilot mHealth (text messages) study reported promising evidence in reducing blood pressure among hypertensive patients in the intervention arm \\[adjusted reduction in systolic blood pressure (BP) -6.50 (95% CI, -12.6; -0.33) and diastolic BP -4.60 (95% CI, -8.16; -1.04)\\], with a greater proportion achieving target BP (70% vs 48% in the control arm, p = 0.006)\\] and improving treatment compliance (p \\\u003C 0.001) in Nepal. This finding supports the expansion to a large-scale trial of a structured mHealth intervention to see its long-term effectiveness and sustainability for patients with HTN to improve BP control and reduce CVD risk. Hence, this study aims to assess the effectiveness of a behavioural intervention through mHealth (telephone\u002Fmobile phone calls and text messages) informed by the RE-AIM framework for improving blood pressure control among patients with hypertension in a hospital (Manamohan Cardiothoracic Vascular and Transplant Center) of Kathmandu, Nepal.",[132,280,28,96],"Medication Adherence",[282,283,132,284],"Mobile Intervention","Blood Pressure Control","Randomized Controlled Trial",{"date":202,"type":33},{"date":287,"type":33},"2025-11-02",{"date":37,"type":21},{"name":290,"class":115},"Central Department of Public Health",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":41},"100609591","the-continuity-study-100609591","NCT07216573","The Continuity Study","Continuous Blood Pressure Monitoring During Outpatient Surgery","Inclusion Criteria:\n\n1. Signed informed consent\n2. Age ≥ 18 years\n3. American Society of Anesthesiologists (ASA) Physical Status ≥ 2\n4. Scheduled for elective noncardiac surgery with intermittent arterial blood pressure monitoring using oscillometric arm cuff\n\nExclusion Criteria:\n\n1. Patient who is known to be pregnant\n2. Patient with existing or planned arterial pressure catheter\n3. Patient in whom systolic arterial pressure differs by more than 20 mmHg between the right and left arms\n4. Inability to place oscillometric cuff on the subject's upper extremity\n5. Extreme contraction of the smooth muscle in the arteries and arterioles of the lower arm and hand, such as may be present in patients with Raynaud's disease\n6. Finger or hand deformity that prevents proper placement of finger cuff by visual inspection\n7. Inability to place finger cuffs due to subject anatomy, condition, or obstructive paraphernalia (such as false nails)",{"count":299,"type":21},188,[24],"A before and after interventional cohort study comparing intermittent blood pressure measurement using the oscillometric arm cuff to continuous noninvasive blood pressure (cNIBP) measurement using the VitaWave finger cuffs in subjects undergoing elective surgery in an outpatient setting.",[28],"2026-06-03",{"date":305,"type":33},"2026-06-04",{"date":307,"type":33},"2026-05-07",{"date":309,"type":21},"2027-02",{"name":311,"class":40},"Edwards Lifesciences",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":328,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":88},"100611457","accuracy-of-a-cuffless-photoplethysmography-ppg-chest-patch-monitor-for-24-hour-ambulatory-blood-pressure-monitoring-abpm-100611457","NCT07240831","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring","PPG ABPM","Inclusion Criteria\n\n* Females and Males subjects 18 years or older (from all skin tones\u002Fcolors)\n* Scheduled for ABPM for hypertension screening, evaluation, or management\n* Subjects capable of using an application temporarily downloaded (for the duration of the study) on a personal smart phone device or on a device provided by the study sponsor\n* Subjects with Atrial fibrillation or Atrial flutter are eligible to participate if standard cuff-based ABPM monitor can capture blood pressure at initialization\n\nExclusion Criteria\n\n* Indication for ABPM is orthostatic hypotension or Postural Orthostatic Tachycardiac Syndrome as indicated on the ABPM referral order\n* Any neurological, psychological, or other condition impairing the ability to provide informed consent or participate in the study\n* Inability to reliably access the Internet via a smart phone\n* Not able to perform standard cuff-based ABPM\n* Average absolute difference between the two arms is greater than 15 mmHg for Systolic Blood Pressure (SBP) or greater than 10 mmHg Diastolic Blood Pressure (DBP) during the initialization\u002Fcalibration phase\n* Subjects with known allergy to adhesives or skin patches\n* Subjects with solid dark tattoos on the area where the PPG-based device is attached\n* Subjects who are unwilling to have their chest hair shaved, if needed, to install the device (the device uses adhesives and needs to be in direct contact with the skin without hair)\n* Subjects who are unwilling to comply with the study instructions (avoid vigorous exercise and showering for 24 hours while the device is in place)",{"count":321,"type":21},600,[24],"This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake\u002FAsleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.",[28,325,326,327],"Heart Disease","Hypertension (HTN)","Blood Pressure Monitoring",[329,330,326,331,332,333,334],"BLOOD PRESSURE","BLOOD PRESSURE MONITORING","CUFFLESS PHOTOPLETHYSMOGRAPHY","PPG","CUFFLESS","vital signs","2026-06-01",{"date":337,"type":33},"2026-06-02",{"date":339,"type":33},"2025-12-15",{"date":341,"type":21},"2026-10-30",{"name":343,"class":40},"Biobeat Technologies Ltd.",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":351,"minAge":124,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":356,"conditions":357,"keywords":362,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":41},"100607902","phase-2-equol-and-vascular-function-in-women-with-chronic-kidney-disease-100607902","NCT07194590","Equol and Vascular Function in Women With Chronic Kidney Disease","Equol Supplementation for Improving Vascular Function in Postmenopausal Women With CKD","Inclusion Criteria:\n\n* Postmenopausal women\n* Aged ≥50 years\n* CKD stage 3 or 4 (eGFR with the CKD-EPI 2021 race-free equation: 15-59 mL\u002Fmin\u002F1.73m2; stable renal function in the past 3 months)\n* Low habitual intake of soy (soy-related food intake \\\u003C 2 times per week assessed by Soy-Specific Food Frequency Questionnaire)\n* Weight stable in the prior 3 months (\\\u003C2 kg weight change) and willing to remain weight stable throughout the study\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with advanced CKD requiring chronic dialysis\n* Uncontrolled hypertension in CKD group (BP \\>140\u002F90 mmHg)\n* Use of any hormone replacement therapy\n* Allergy and\u002For intolerance to soy or soy-based products\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values 2X upper limit of normal range (upper limit of normal range AST: 117 U\u002FL; ALT: 52 U\u002FL; total bilirubin: 1.3 mg\u002FdL)\n* History of breast cancer\n* Significant co-morbid conditions with a life expectancy of \\\u003C 1 year\n* Current tobacco or nicotine use or history of use in the last 12 months\n* History of kidney transplant\n* History of severe congestive heart failure (i.e., ejection fraction \\\u003C35%)\n* History of hospitalization within the last month\n* Immunosuppressant agents taken in the past 12 months\n* Known malignancy","FEMALE",{"count":353,"type":21},74,[355],"PHASE2","The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH.\n\nEquol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.",[358,359,360,361,28],"Chronic Kidney Disease (Stage 3-4)","Vascular Function","Cognitive Functions","Cerebrovascular Function",[363,284,364,365,359],"S-equol","Chronic Kidney Disease","Women's Health",{"date":337,"type":33},{"date":368,"type":33},"2026-02-19",{"date":370,"type":21},"2030-11-30",{"name":372,"class":115},"University of Colorado, Denver",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":48,"sex":17,"minAge":381,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":385,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":41},"100325189","early-phase-1-autonomic-control-of-the-circulation-and-vdr-100325189","NCT03513770","Autonomic Control of the Circulation and VDR","Autonomic Control of the Circulation and the Venous Distension Reflex","VDR","Inclusion Criteria\n\n* Are capable of giving informed consent\n* Are any race or ethnicity\n* Are fluent in written and spoken English\n* Have a satisfactory history and physical exam to meet inclusion\u002Fexclusion criteria\n* Are free of acute or chronic medical conditions\n* Are 21 - 35 years of age (inclusive)\n* Weigh over 50 kg\n\nExclusion Criteria\n\n* Are less than 21 or over 35 years of age\n* Are Pregnant or nursing women\n* Are prisoners or institutionalized individuals or unable to consent\n* Any chronic diseases (hypertension, heart, lung, neuromuscular disease, kidney disease, diabetes or cancer).\n* Are taking medications that may affect their cardiovascular or nervous system\n* Has taken an NSAID within 48 hours of any visit (visit will need to be rescheduled)\n* Has never taken NSAIDs and therefore would not know if they are allergic to it\n* Have a supine BP \\>140\u002F90 mmHg\n* Have known allergy to ibuprofen-like drugs (NSAIDS) or aspirin\n* Have history of asthma or nasal polyps\n* Have history of GI bleeding or ulcers\n* Subjects with ferromagnetic metal implants\n* Subjects who are claustrophobic","21 Years","35 Years",{"count":384,"type":21},18,[386],"EARLY_PHASE1","The study objective of this project is to examine the mechanisms of the venous distension reflex (VDR) in humans. We hypothesize that COX blockade with ketorolac tromethamine, an intravenous NSAID, will attenuate the muscle sympathetic nerve activity (MSNA) response to limb venous distension. To gain further insight into whether the COX byproducts directly stimulate chemically-sensitive afferents, or enable venodilation and indirectly evoke afferent stimulation, we will measure vein size using 3T MRI during venous distention with and without ketorolac infusions.",[389,28],"Venous Distension Reflex","2026-05-29",{"date":337,"type":33},{"date":393,"type":33},"2019-08-14",{"date":395,"type":21},"2027-08-31",{"name":397,"class":115},"Milton S. Hershey Medical Center",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":48,"sex":17,"minAge":219,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":41},"100538064","the-dream-study-a-multidimensional-sleep-health-intervention-for-improving-cardiometabolic-health-100538064","NCT06285968","The DREAM Study: A Multidimensional Sleep Health Intervention for Improving Cardiometabolic Health","Addressing Sleep Duration, Regularity, and Efficiency: A Multidimensional Sleep Health Intervention for Improving Cardiometabolic Health (The DREAM Study)","Inclusion Criteria:\n\n* Adults aged 30+ years\n* English or Spanish speaking\n* Systolic blood pressure greater than or equal to 120 mmHg\n* Sub-optimal sleep health\n* No history of overt cardiovascular disease\n* No history of cancer\n\nExclusion Criteria:\n\n* Optimal sleep health\n* History of cardiovascular disease or cancer\n* Non-English or non-Spanish speaking\n* Not cognitively able to complete study requirements\n* Severe psychiatric disorders\n* Inability to provide informed consent",{"count":406,"type":21},200,[24],"The purpose of this randomized clinical trial is to evaluate the impact of a multidimensional sleep health promotion intervention on blood pressure, glycemic control indicators, anthropometric markers of adiposity, and lifestyle factors in adults. Participants will be randomized into an intervention or a control group. The control arm will receive standard Life's Essential 8 cardiovascular health educational materials. The intervention arm will additionally receive a multi-component intervention aimed at improving sleep health based on evidence-based sleep hygiene education and established behavior change techniques that include personalized sleep health feedback, goal setting and establishing a sleep health plan, coaching, self-monitoring, and addressing light and noise in the sleep environment. Mixed methods will be used to understand implementation determinants, processes, and outcomes, ensuring the successful completion and future expansion of this intervention.",[28],"2026-05-27",{"date":390,"type":33},{"date":413,"type":33},"2024-03-12",{"date":77,"type":21},{"name":238,"class":115},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":48,"sex":17,"minAge":124,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":435,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":41},"100479368","reducing-blood-pressure-in-mid-life-adult-binge-drinkers-100479368","NCT05522075","Reducing Blood Pressure in Mid-life Adult Binge Drinkers","Reducing Blood Pressure in Mid-life Adult Binge Drinkers: the Role of Microvascular Function and Sympathetic Activity","Inclusion Criteria:\n\n* Men and women (50-64 years of age) who do not drink alcohol, who drink at moderate levels, or who binge drink\n* Female subjects will be postmenopausal (i.e., cessation of menses for ≥1 yr).\n* Subjects who can speak and understand English.\n\nExclusion Criteria:\n\n* a history of diabetes, cardiovascular disease, liver, or renal disease\n* current or history of smoking and illicit drug use\n* blood pressure ≥160\u002F100 mm Hg\n* other known traditional cardiovascular disease risks: obesity (BMI≥35 kg\u002Fm2), or hyperlipidemia (total cholesterol\\>230 mg\u002Fdl and\u002For LDL cholesterol\\>160 mg\u002Fdl)\n* active infection (in the past 2 months)\n* a history of seizures, cancer, or inflammatory disease (i.e., gout or rheumatoid)\n* unstable body weight (\\>5% change during the past 6 months)\n* regular aerobic exercise training (i.e., they engage in 30 min of structured aerobic exercise at least 3 times per week)\n* current use of hormone replacement therapy (i.e., estrogen, progesterone, and testosterone)","64 Years",{"count":425,"type":21},55,[24],"This study has two phases:\n\nPhase 1 is to examine blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers vs. alcohol abstainers\u002Fmoderate drinkers.\n\nPhase 2 is to examine the effect of 8-week aerobic exercise training on blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers",[429,430,28,431,133,432,433,434],"Alcohol Drinking","Binge Drinking","Alcohol Abstinence","Lifestyle Factors","Vasodilation","Behavioral Problem",[436,437,438,439,440,441],"Exercise training","High-intensity interval training","Midlife adults","Middle-aged","Microvascular function","Sympathetic nerve activity",{"date":335,"type":33},{"date":444,"type":33},"2022-11-21",{"date":446,"type":21},"2027-04-30",{"name":448,"class":115},"The University of Texas at Arlington",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":41},"100638584","consciousness-studies-and-cardiovascular-health-100638584","NCT07620639","Consciousness Studies and Cardiovascular Health","Inclusion Criteria:\n\n* Age 18 and older\n* Able to provide informed consent (English only for pilot)\n* Chronic Selective Serotonin Reuptake Inhibitors\u002F Serotonin-norepinephrine reuptake inhibitors (SSRI\u002FSNRI) or Attention Deficit\u002F Hyperactivity Disorder (ADHD) meds allowed (recorded)\n* Normal vision and hearing\n* Stable vitals (HR 55-100 bpm, Systolic Blood Pressure (SBP) 90-160mmHg (millimeters of mercury, afebrile)\n* Willing to abstain 6 hours pre-session from caffeine, nicotine, heavy exercise\n* Willing to tolerate electroencephalogram (EEG) headband, Galvanic Skin Response (GSR) electrodes are small sensors placed on the skin (usually fingers or palm) and virtual reality (VR) headset\n\nExclusion Criteria:\n\n* History of seizure disorder or photosensitive epilepsy\n* Migraine with visual aura\n* Retinal disease sensitive to flicker\n* Unstable cardiac disease\n* Dysautonomia\n* Recent sedative use (benzodiazepines, opioids)\n* Beta blocker dose changes within last 7 days\n* Alcohol or recreational drugs within 12 hours\n* Active panic disorder\n* Severe motion sickness\n* Scalp conditions preventing EEG contact\n* Severe visual or hearing impairment Cognitive impairment\n* Non-English speakers (pilot in English only)",{"count":456,"type":21},40,[24],"The objective of the study is to evaluate whether a virtual reality (VR) based intervention combining binaural beats, photic stimulation, and real-time biofeedback reduces stress and improves physiological markers compared to non-VR interventions and usual care in patients that go to cardiology clinic.",[28,460,461],"Relaxation","Virtual Reality","2026-05-26",{"date":337,"type":33},{"date":465,"type":21},"2026-10",{"date":467,"type":21},"2028-10",{"name":469,"class":115},"University of Miami",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":48,"sex":17,"minAge":477,"maxAge":478,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":488,"leadSponsor":490,"locationsCount":41},"100640351","a-study-of-starting-strength-barbell-training-100640351","NCT07578285","A Study Of Starting Strength Barbell Training","Effects Of Progressive Barbell Strength Training On Cardiovascular And Metabolic Health Markers","Inclusion Criteria:\n\n* Adults aged 18-100 years\n* Sedentary or minimally active (less than 150 minutes of moderate-intensity physical activity per week)\n* No participation in structured resistance training programs within the past 6 months.\n* Able to safely participate in resistance training as determined by medical screening\n* Willing to commit to 3 training sessions per week for 12 weeks\n* Able to provide informed consent\n* Willing to obtain pre- and post-intervention laboratory tests from the same laboratory company.\n\nExclusion Criteria:\n\n* Current participation in structured resistance training programs\n* Cardiovascular disease requiring activity restriction\n* Uncontrolled hypertension (systolic BP \\>180 mm Hg or diastolic BP \\>110 mm Hg)\n* Musculoskeletal conditions precluding safe barbell training\n* Changes in lipid-lowering or antihypertensive medications within 3 months prior to enrollment\n* Known cardiovascular, metabolic, or renal disease that would preclude safe participation in resistance training","15 Years","100 Years",{"count":406,"type":21},[24],"The purpose of this study is to determine the effect of a 12-week coached Starting Strength barbell training program on systolic and diastolic blood pressure.",[28,483,167],"Lipid Profile","2026-05-05",{"date":486,"type":33},"2026-05-11",{"date":335,"type":21},{"date":489,"type":21},"2029-01-01",{"name":491,"class":115},"Mayo Clinic",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":351,"minAge":499,"maxAge":382,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":514,"locationsCount":41},"100638110","effects-of-breathing-retraining-exercises-in-pregnant-females-with-postural-orthostatic-tachycardia-syndrome-100638110","NCT07579026","Effects of Breathing Retraining Exercises in Pregnant Females With Postural Orthostatic Tachycardia Syndrome.","Effects of Breathing Retraining Exercises on Heartrate, Blood Pressure and Orthostatic Intolerance in Pregnant Females With Postural Orthostatic Tachycardia Syndrome.","Inclusion Criteria:\n\n* • Pregnant female between the age of 19 to 35 years.\n\n  * Active standing results in a sustained increase in heart rate (HR) of at least 30 bpm or ≥120 bpm.\n  * POTS patients with a subacute onset of lightheadedness, dizziness, and presyncope provoked by standing.\n  * palpitations with chest discomfort, breathing difficulties, or feeling faint\n\nExclusion Criteria:\n\n* • Uncontrolled hypertension\u002Fpre-eclampsia\n\n  * cardiovascular disorder\n  * Patients with uncontrolled diabetes\n  * Patient with Anemia, severe heart failure and neurodegenerative diseases.\n  * Females with the history of deep venous thrombosis.","19 Years",{"count":501,"type":21},44,[24],"Postural orthostatic tachycardia POTS is characterized by excessive increase in heart rate when moving from lying to standing position, often accompanied by symptoms such as dizziness, fatigue, brain fog, lightheadedness, rapid heartbeat and palpitation.it most commonly effects the females of reproductive age and can be triggered by events like viral infections, trauma and hormonal changes. During pregnancy females may experience worsening of symptoms in first trimester due to hormonal changes and decreased blood volume later on in second and third trimester the blood volume begins to increase. However, breathing exercises helps to regulate the nervous system, improves parasympathetic activity and reduce sympathetic activity.\n\nThe study will be randomized clinical trial and will be conducted at Bashir hospital Sialkot and Fatima hospital Sialkot. The study will be completed in 10 months of duration after the approval of synopsis. Non probability convenience sampling will be used and 44 participants will be included in the study after randomization. The subjects will be divided into two groups. Group A (experimental group) will receive diaphragmatic breathing exercises whereas Group B (control group) will receive educational retraining whereas both groups will receive baseline treatments which includes progressive muscle relaxation techniques. The tools used for the study will be Vanderbilt orthostatic symptom score VOSS to evaluate orthostatic intolerance, blood pressure will be measured using non-invasive blood pressure measurement and pulse oximetry will be used to access the heart rate. After data completion data will be analyzed by using SPSS version 21.",[94,505,28],"Heart Rate",[507,104,334,508,509],"pregnancy","orthostatic intolerance","postural orthostatic tachycardia syndrome",{"date":486,"type":33},{"date":512,"type":33},"2025-08-31",{"date":110,"type":21},{"name":515,"class":115},"Riphah International University",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":17,"minAge":381,"maxAge":523,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":41},"100610775","phase-2-synthetic-thc-and-blood-pressure-100610775","NCT07231965","Synthetic THC And Blood Pressure","Effects Of Cannabis Products On Blood Pressure Control","Inclusion Criteria\n\n* Recreational occasional Cannabis use (Consuming THC less than 2 times a week)\n* 21 - 40 years of age\n* Biological male or female\n\nExclusion Criteria\n\n* BMI \\> 35 kg\u002Fm2\n* Diagnosed psychiatric disorders\n* Hypotension\n* History of seizures\n* History of substance abuse or recreational drug use or positive urine drug screen\n* History of uncontrolled disease including:\n\n  * Cardiovascular\n  * Pulmonary\n  * Gastrointestinal\n  * Pancreatic\n  * Hepatic\n  * Renal\n  * Hematological\n  * Endocrine (including Type I Diabetes)\n  * Neurological\n  * Urological\n  * Sleep disorders\n* Pregnant or breastfeeding\n* Use of certain antimicrobial, chemotherapeutic, anticoagulant, hypoglycemic, anti-inflammatory, psychotropic, and antihistamine drugs\n* Prescribed CYP2C9 and\u002For CYP3A4 inhibitors\n* History of shift work or rotating shifts within 1 month","40 Years",{"count":222,"type":21},[355,526],"PHASE3","To investigate the effects of Dronabinol use on blood pressure and neurovascular physiology",[28],{"date":307,"type":33},{"date":531,"type":21},"2026-07",{"date":533,"type":21},"2027-12",{"name":491,"class":115},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":351,"minAge":543,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":22,"phases":546,"briefSummary":547,"conditions":548,"keywords":565,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":580,"locationsCount":41},"100636706","improved-child-nutrition-and-development-through-social-transfers-100636706","NCT07569172","Improved Child Nutrition and Development Through Social Transfers","Taabo Enhanced Nutrition and Development Through Economic Rewards","TENDER","Inclusion Criteria:\n\n1. Are enrolled in the Taabo multigenerational birth cohort (MGC)\n2. Completed the postpartum interview of the Taabo MGC\n3. Have a child who is within two weeks of their 12-month birthday,\n4. are breastfeeding at time of recruitment,\n5. live in the Taabo HDSS, Côte d'Ivoire\n6. have no illnesses that contraindicates breastfeeding,\n7. had a healthy singleton infant with a birth weight of at least 2500 grams, and\n8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent\n\nExclusion Criteria:\n\n1. Plans to move permanently outside study area\n2. Has a medical, intellectual or psychological disability\n3. Contraindication for breastfeeding\n4. Children born with \\\u003C 2500 grams","12 Years",{"count":545,"type":21},1040,[24],"The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:\n\n* Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?\n* Does the social transfer increase complementary breastfeeding duration?\n* Does the social transfer impact child health and development?\n* Does the social transfer impact maternal physical and mental health?\n\nResearchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.\n\nParticipants will:\n\nReceive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire",[549,550,551,552,553,554,555,556,557,558,28,559,560,561,562,563,564],"Breastfeeding","Breastfeeding Education","Breastfeeding Duration","Breastfeeding Continuation","Child Growth","Stress","Infectious Diseases","Anemia","Child Development","Weight Loss","Mental Health","Diarrhea","Coughing","Eczema","Allergies","Antibiotic Use",[566,567,568,569,570,571,572,573],"breastfeeding","cash transfer","child health","maternal health","mental health","child growth","child development","education","2026-04-28",{"date":576,"type":33},"2026-05-06",{"date":335,"type":21},{"date":579,"type":21},"2028-02-28",{"name":581,"class":115},"Swiss Tropical & Public Health Institute",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":523,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":592,"briefSummary":593,"conditions":594,"keywords":604,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":613,"locationsCount":41},"100595769","enjoying-affordable-and-tasty-food-together-100595769","NCT07036757","Enjoying Affordable and Tasty Food Together","PROJECT EATT: Enjoying Affordable and Tasty Food Together","PROJECT EATT","Inclusion Criteria:\n\n* Adults aged 40 years and older.\n* Household income at or less than the 200% the federal poverty level (household size 1: $30,120, household size 2: $40,880, household size 3: $51,640, household size 4: $62,400, and household size 5: $73,160)\n* Willing to provide informed consent and complete the study requirements, including attending study visits and completing questionnaires.\n* Access to a refrigerator or other means to safely store perishable food, as the meal kits require refrigeration.\n* BMI \\> 30 kg\u002Fm2 and self-report having at least one of the following: elevated blood pressure or hypertension, elevated glucose, prediabetes or diabetes.\n* Reside in the Greater Lowell area or surrounding regions to ensure feasibility of meal kit delivery and data collection.\n\nExclusion Criteria:\n\n* Less than 40 years old\n* Does not have BMI \\>30 kg\u002Fm2, elevated blood pressure or hypertension, or elevated glucose, prediabetes or diabetes\n* Not able to provide consent (adults lacking capacity)\n* Follow a medically restricted diet or have allergies to wheat, soy, or dairy\n* Plans to move from the Greater Lowell area within the next 12 months\n* Live outside the Greater Lowell area because this will impact meal kit delivery\n* Individuals without a working refrigerator in your household\n* Have a serious medical condition requiring a doctor's care including cancer, chronic kidney disease and\u002For celiac disease\n* Currently part of a study on diabetes, cardiovascular disease, nutrition or weight-loss\n* Currently taking any weight loss medication like Ozempic, or medication for diabetes, dyslipidemia or hypertension\n* Currently using a continuous glucose monitor",{"count":591,"type":21},120,[24],"The goal of this pilot study is to examine the feasibility of a novel meal kit and nutrition education intervention among adults aged 40 years and older, who are lower income, and to evaluate the preliminary impact of the meal kit and nutrition education intervention on food insecurity, dietary quality, mental health, quality of life and cardiovascular risk factors compared with general nutrition education materials in this population.\n\nThe main questions are:\n\nWhat is the acceptability and satisfaction with the meal kits and nutrition education intervention?\n\nWhat are the participation rates in the nutrition education program and the evaluation of the intervention?\n\nWhat is the impact of the intervention on food insecurity, dietary quality and cooking and food preparation self-efficacy compared with general nutrition education materials?\n\nWhat is the impact of the intervention of psychosocial health, quality of life and cardiometabolic outcomes compared with general nutrition education materials?",[595,596,597,598,599,600,601,602,603,28],"Food Insecurity","Dietary Quality","Quality of Life","Cooking Self-efficacy","Perceived Stress","Anxiety","Depressive Symptomatology","Anthropometrics: Height and Weight","Glucose Variability",[605,606,607,608,597],"Nutrition Education","Cardiometabolic outcomes","Meal Kits","Stress and Mental Health",{"date":484,"type":33},{"date":611,"type":33},"2026-02-01",{"date":341,"type":21},{"name":614,"class":115},"University of Massachusetts, Lowell",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":622,"enrollmentInfo":623,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":41},"100305377","phase-1-cerebral-blood-flow-and-ventilatory-responses-during-sleep-in-normoxia-and-intermittent-hypoxia-100305377","NCT03255408","Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia","Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia","Inclusion Criteria:\n\n* Healthy adults\n* 18 - 45 years of age\n* Living in Calgary for the past one year\n* Have no medical condition or should not be taking any blood pressure medications.\n* The participant should not be lactose intolerant\n\nExclusion Criteria:\n\n* Cerebrovascular, cardio-respiratory, renal and metabolic diseases\n* Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease\n* Pregnancy, obese and sleep-disordered breathing\n* Drug allergies to non-steroidal anti-inflammatories\n* Currently smoking","45 Years",{"count":624,"type":21},12,[626,355],"PHASE1","A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).",[629,630,631,632,633,28,634,635],"Obstructive Sleep Apnea of Adult","Hypoxia, Brain","Sleep Apnea","Sleep Disorder","Stroke","Endothelial Dysfunction","Oxidative Stress","2026-04-27",{"date":638,"type":33},"2026-05-01",{"date":640,"type":33},"2023-01-01",{"date":642,"type":21},"2027-12-30",{"name":644,"class":115},"University of Calgary",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":423,"enrollmentInfo":651,"targetDuration":4,"studyType":652,"phases":4,"briefSummary":653,"conditions":654,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":659,"leadSponsor":661,"locationsCount":4},"100537014","vital-signs-blood-pressure-trial-100537014","NCT06272318","Vital Signs Blood Pressure Trial","Inclusion Criteria:\n\n* Age \\>17 and \\\u003C65 years\n* BMI \\>20 and \\\u003C35\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>64\n* BMI \\\u003C20 or \\>35\n* Pregnancy",{"count":222,"type":21},"OBSERVATIONAL","The purpose of this study is collect subject vitals with a blood pressure cuff, electrocardiogram (ECG), and photoplethysmogram (PPG). This data can then be used to develop a reliable, accurate, noninvasive, and continuous blood pressure monitoring device.",[96,132,28],"2026-04-21",{"date":657,"type":33},"2026-04-24",{"date":638,"type":21},{"date":660,"type":21},"2026-09-30",{"name":662,"class":115},"Stanford University",{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":12,"sex":17,"minAge":154,"maxAge":669,"enrollmentInfo":670,"targetDuration":4,"studyType":22,"phases":672,"briefSummary":673,"conditions":674,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":41},"100634461","evaluation-of-a-novel-indoor-air-pollution-intervention-among-older-adults-100634461","NCT07539987","Evaluation of a Novel Indoor Air Pollution Intervention Among Older Adults","Inclusion Criteria:\n\n* 55-79 years of age one primary residence (5+ days per week)\n* have an electronic device, email address, and reliable internet at home for survey submission\n\nExclusion Criteria:\n\n* current smoking of any kind or living in a household with someone who currently smokes\n* current use of a portable air cleaner unit at home\n* plans to move in the next year\n* previous physician-diagnosed cardiovascular disease (coronary heart disease \\[myocardial infarction\\], stroke, or heart failure)","79 Years",{"count":671,"type":21},154,[24],"Particulate matter air pollution is the leading environmental risk factor of cardiovascular disease and is increasing in the Western United States due to more frequent and severe wildfires. Older adults are particularly susceptible to both air pollution exposures and the development of cardiovascular disease, and the older adult population in the United States is rapidly growing. Given the converging threats of worsening air quality and an aging population, this clinical trial will evaluate a novel, multifaceted indoor air quality intervention to improve cardiovascular health outcomes among older adults in the wildfire-impacted state of Montana.",[96,28,675,676,677,678,679,680,681],"Glycated Hemoglobin (HbA1c)","Cholesterol","Cholesterol, HDL","Cholesterol, LDL","Indoor Air Quality","Particulate Matter","Health Behavior","2026-04-13",{"date":684,"type":33},"2026-04-20",{"date":686,"type":21},"2026-08",{"date":688,"type":21},"2030-07",{"name":690,"class":115},"University of Montana"]